Aethlon Medical (NASDAQ:AEMD) Trading Up 19.3%

Shares of Aethlon Medical, Inc. (NASDAQ:AEMD) were up 19.3% during trading on Thursday . The stock traded as high as $2.70 and last traded at $2.47. Approximately 3,514,027 shares changed hands during mid-day trading, an increase of 93% from the average daily volume of 1,824,501 shares. The stock had previously closed at $2.07.

The company has a 50 day moving average of $1.82 and a 200 day moving average of $1.72.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Monday, November 2nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.03). Equities research analysts predict that Aethlon Medical, Inc. will post -0.55 earnings per share for the current year.

In other Aethlon Medical news, Director Chetan Shah sold 26,852 shares of Aethlon Medical stock in a transaction on Thursday, December 17th. The stock was sold at an average price of $2.11, for a total value of $56,657.72. Following the completion of the transaction, the director now owns 22,392 shares in the company, valued at approximately $47,247.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.67% of the company’s stock.

A hedge fund recently bought a new stake in Aethlon Medical stock. Two Sigma Securities LLC bought a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,087 shares of the medical equipment provider’s stock, valued at approximately $27,000. Two Sigma Securities LLC owned about 0.11% of Aethlon Medical as of its most recent SEC filing. Institutional investors own 2.37% of the company’s stock.

About Aethlon Medical (NASDAQ:AEMD)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system.

Featured Story: Lock-Up Period Expiration

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with's FREE daily email newsletter.